This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pot-stocks: Archive
Cannabis Operator CRON Rises 46% in a Year: Time to Buy, Sell or Hold?
by Sundeep Ganoria
Cronos stock jumps 46% on strong international growth, margin expansion, and reform optimism; can the company sustain momentum amid rising competition?
CRONNegative Net Change TLRYNegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Cannabis Operator GTBIF Stock Down 17% YTD: Should You Buy the Dip?
by Sundeep Ganoria
Green Thumb has lost 17% YTD as pricing pressure and competition weigh, but steady revenue growth and strong cash flow raise the question: Is the dip worth buying?
TLRYNegative Net Change GTBIFNegative Net Change CRLBFNegative Net Change
marijuana medical pot-stocks
Should Cresco Stock Be in Your Portfolio Post Q4 Earnings?
by Sundeep Ganoria
CRLBF faces US pricing pressure despite a Q4 sales beat and a strategic entry into Germany's cannabis market, raising questions about near-term upside.
CGCNegative Net Change TLRYNegative Net Change CRLBFNegative Net Change
marijuana medical pot-stocks
Jazz Pharmaceuticals' CBD Drug Hits $1B: Time to Buy the Stock?
by Sundeep Ganoria
JAZZ CBD drug Epidiolex tops $1B in annual sales, boosting revenue visibility and cannabis exposure. Is the biotech's growth story just beginning?
JAZZNegative Net Change TLRYNegative Net Change ACBNegative Net Change
biotechs marijuana medical pot-stocks
SNDL Stock Loses 31% in Six Months: Should You Buy the Dip?
by Sundeep Ganoria
SNDL stock is down 31% in six months, but cannabis sales are up 16%, and free cash flow has turned positive. Can growth offset fierce competition?
TLRYNegative Net Change SNDLNegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Should Canopy Growth Stock Be in Your Portfolio Post Q3 Earnings?
by Sundeep Ganoria
CGC beats Q3 estimates as Canadian cannabis sales rise, but margin pressure and global volatility cloud its path to sustained profitability.
CGCNegative Net Change TLRYNegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Should You Buy, Hold or Sell ACB Stock Post Q3 Earnings Release?
by Sundeep Ganoria
Aurora Cannabis beat Q3 earnings and sales estimates as medical cannabis momentum drove growth, but persistent consumer weakness pressured the stock outlook.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change
marijuana medical pot-stocks
Curaleaf Announces Delaware Domestication Plan: How to Play the Stock?
by Sundeep Ganoria
CURLF's Delaware domestication plan could streamline governance and enhance capital market flexibility as U.S. pressure persists and international growth builds.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Should You Buy ACB Stock After Marijuana Reclassification Order?
by Sundeep Ganoria
Aurora Cannabis faces uneven gains from marijuana reclassification as medical cannabis drives growth, while weak consumer sales affect optimism.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change
marijuana medical pot-stocks
Should You Buy GTBIF Stock After Marijuana Reclassification Order?
by Sundeep Ganoria
Shares of Green Thumb GTBIF jump nearly 35% on a marijuana rescheduling order, but pricing pressure and weak comps cloud the stock's near-term outlook.
CGCNegative Net Change GTBIFNegative Net Change CRLBFNegative Net Change
marijuana medical pot-stocks